Invalid Symbol

Stock Research for BLRX

BLRX
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

BLRX Stock Chart & Research Data

The BLRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BLRX Due diligence Resources & Stock Charts

The BLRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLRX Detailed Price Forecast - CNN Money CNN View BLRX Detailed Summary - Google Finance
Yahoo View BLRX Detailed Summary - Yahoo! Finance Zacks View BLRX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View BLRX Trends & Analysis - Trade-Ideas Barrons View BLRX Major Holders - Barrons
NASDAQ View BLRX Call Transcripts - NASDAQ Seeking View BLRX Breaking News & Analysis - Seeking Alpha
Spotlight View BLRX Annual Report - CompanySpotlight.com OTC Report View BLRX OTC Short Report - OTCShortReport.com
TradeKing View BLRX Fundamentals - TradeKing Charts View BLRX SEC Filings - Bar Chart
WSJ View Historical Prices for BLRX - The WSJ Morningstar View Performance/Total Return for BLRX - Morningstar
MarketWatch View the Analyst Estimates for BLRX - MarketWatch CNBC View the Earnings History for BLRX - CNBC
StockMarketWatch View the BLRX Earnings - StockMarketWatch MacroAxis View BLRX Buy or Sell Recommendations - MacroAxis
Bullish View the BLRX Bullish Patterns - American Bulls Short Pains View BLRX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View BLRX Stock Mentions - StockTwits PennyStocks View BLRX Stock Mentions - PennyStockTweets
Twitter View BLRX Stock Mentions - Twitter Invest Hub View BLRX Investment Forum News - Investor Hub
Yahoo View BLRX Stock Mentions - Yahoo! Message Board Seeking Alpha View BLRX Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for BLRX - SECform4.com Insider Cow View Insider Transactions for BLRX - Insider Cow
CNBC View BLRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLRX - OTC Markets
Yahoo View Insider Transactions for BLRX - Yahoo! Finance NASDAQ View Institutional Holdings for BLRX - NASDAQ


Stock Charts

FinViz View BLRX Stock Insight & Charts - FinViz.com StockCharts View BLRX Investment Charts - StockCharts.com
BarChart View BLRX Stock Overview & Charts - BarChart Trading View View BLRX User Generated Charts - Trading View


Latest Financial News for BLRX

BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13
Posted on Tuesday February 06, 2018

TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...


BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
Posted on Tuesday January 23, 2018

BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA) a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the publication of data showing that BL-8040, its lead oncology platform, augments the ability of the immune system to fight cancer by increasing the infiltration of anti-tumor-specific T-cells into the tumor microenvironment (TME), resulting in decreased tumor growth and prolonged survival in a murine model of cancer. Results of the study will be presented as a poster titled "CXCR4 Antagonist (BL-8040) Enhances Antitumor Effects by Increasing Tumor Infiltration of Antigen-specific Effector T-cells" (Abstract 73) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. In the preclinical study, a murine model of cancer was used to assess the effects of BL-8040 in combination with a cancer vaccine that primes the immune system against the tumor.


BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
Posted on Tuesday January 23, 2018

BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an immunotherapy compound in development for the treatment of multiple solid tumors, demonstrated successful results in two pre-clinical melanoma studies. Results of these studies will be presented as a poster titled "Intratumoral Administration of the Alpha-Gal Glycolipid AGI-134 to Induce Tumor Regression in a Mouse Model of Melanoma" (Abstract 68) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. The ability of intratumorally injected AGI-134 to induce regression of established primary tumors was assessed in two murine melanoma models.


BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
Posted on Thursday January 18, 2018

BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.


BiolineRx Has Huge Upside In 2018
Seeking Alpha - Jan 29, 2018
In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents.

Investors Waiting In BioLineRx
Seeking Alpha - Jul 18, 2017
BioLineRx (BLRX) is a $90 million market cap clinical-stage company, focused on immunology and oncology. The company in-licenses preclinical and clinical stage projects, then partners for advanced clinical stages and commercialization.

BioLineRx: Why I See Significant Upside Potential In This $1 Biotech Stock
Seeking Alpha - Sep 1, 2017
BioLineRx shares have dipped from recent highs and this has created an attractive buying opportunity. This company has a very promising pipeline, multiple partnerships, a cash-rich balance sheet and a low burn rate which reduces potential downside ...

BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in ...
PR Newswire (press release) - Jan 17, 2018
TEL AVIV, Israel, Jan. 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today partial results from the monotherapy portion of BL-8040's Phase ...

Enter a stock symbol to view the stock details.